ADC Therapeutics SA
ADCT· NYSE
Released Nov 10, 2025, before the open
10-Q filed Nov 10, 2025, 41 days after period end · 0001628280-25-051095
| Metric | Q3 2025 | Q3 2024 | Q3 2023 | Q3 2022 |
|---|---|---|---|---|
| Revenue | $15.75M | $18.02M | $14.27M | $76.32M |
| Net Income | -$40.97M | -$43.97M | -$46.73M | -$50.61M |
| EPS Diluted |
ADC Therapeutics SA · CIK 1771910 · Engraved from SEC EDGAR
| -$0.30 |
| -$0.42 |
| -$0.57 |
| -$0.65 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.